Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpheniramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.97 |
| ▸ | HTR2A | P28223 | 3/20 | 0.97 |
| ▸ | SCN1A | P35498 | 3/20 | 0.97 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.97 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | THPO | P40225 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexchlorpheniramine SCHEMBL31134035 | 1.00 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL506016 | 1.00 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4314182 | 0.99 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Dexchlorpheniramine SCHEMBL3538 | 0.99 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL20956397 | 0.99 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL29687335 | 0.99 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4219 | 0.99 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4220 | 0.99 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL5022351 | 0.97 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL14879822 | 0.97 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022241985-A1 | USE OF H1 HISTAMINE RECEPTOR ANTAGONIST IN PREPARATION OF DRUG FOR TREATING GLIOMA | 温州医科大学附属第一医院 | 2022-11-24 | — | — | WO | claimed |
| WO-2019233496-A1 | APPLICATION OF CINNAMALDEHYDE AND/OR ALLANTOIN TO REPLACE HIGH ZINC AMOUNTS IN SUCKLING PIGLET FEED, FEED ADDITIVE OR ADDITIVE PREMIX, AND FEED | 湖南晶天科技实业有限公司 (CN) | 2019-12-12 | — | — | WO | claimed |
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-6159498-A | WATER-SOLUBLE DELIVERY DEVICE FOR APPLICATION TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| EP-4746862-A2 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | Aquestive Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075448-A | Pharmaceutical composition with enhanced permeation | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026090119-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108422-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12491166-B2 | Method of delivering an active compound and delivery device for use in the same | WACKER CHEMIE AG (DE) | 2025-12-09 | — | — | US | disclosed |
| WO-1999004764-A1 | TANNIC ACID-POLYMER COMPOSITIONS FOR CONTROLLED RELEASE OF PHARMACEUTICAL AGENTS, PARTICULARLY IN THE ORAL CAVITY | PERIO PRODUCTS LTD. (IL) | 1999-02-04 | — | — | WO | disclosed |
| US-5800832-A | MULTILAYER DEVICE FOR DRUG DELIVERY, ADHESIVES LAYER AND BACKINGS | VIROTEX CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1998017252-A1 | PHARMACEUTICAL GEL PREPARATION APPLICABLE TO MUCOSAL SURFACES AND BODY TISSUES | VIROTEX CORPORATION (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998017251-A1 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0275550-B1 | ADHESIVE DEVICE FOR APPLICATION TO BODY TISSUE | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1993-04-21 | — | — | EP | disclosed |
| US-5126145-A | Hydroxypropylmethyl cellulose, binder, hydrophobic component | TCF BANK SAVINGS FSB N/K/A TCF NATIONAL BANK | 1992-06-30 | — | — | US | disclosed |
| US-4900554-A | ACRYLIC ACID POLYMER AND CELLULOSE DERIVATIVE BLEND FOR ORAL CAVITY USE | TEIKOKU SEIYAKU CO., LTD. (JP) | 1990-02-13 | — | — | US | disclosed |
| EP-0275550-A1 | Adhesive device for application to body tissue | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491166-B2 | Method of delivering an active compound and delivery device for use in the same | MMP8, CLPP, MMP7 | HRH1 3265/4885CHRM2 1498/4885SLC6A2 1323/4885 |
| US-20260108458-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS TO TREAT ALLERGY | ADRB1, ADRB2, ADRA1D | HRH1 92/4885CHRM2 65/4885SLC6A2 10/4885 |
| US-20260108422-A1 | PHARMACEUTICAL FILM STORAGE AND DISPENSER DEVICE | ICAM1, GJA1, ICOS | HRH1 336/4885CHRM2 996/4885SLC6A2 1073/4885 |
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | HRH1 3232/4885CHRM2 825/4885SLC6A2 188/4885 |
| US-20260027045-A1 | METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRB1, ADRB2, ADRA1D | HRH1 348/4885CHRM2 89/4885SLC6A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.